Fujiang Xu

977 total citations
13 papers, 281 citations indexed

About

Fujiang Xu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Fujiang Xu has authored 13 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Fujiang Xu's work include Renal cell carcinoma treatment (7 papers), Ferroptosis and cancer prognosis (7 papers) and RNA modifications and cancer (2 papers). Fujiang Xu is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Ferroptosis and cancer prognosis (7 papers) and RNA modifications and cancer (2 papers). Fujiang Xu collaborates with scholars based in China. Fujiang Xu's co-authors include Yuanyuan Qu, Kun Chang, Jian‐Yuan Zhao, Chenji Wang, Dingwei Ye, Guohai Shi, Ning Xu, Pengcheng Lin, Yiping Zhu and Wei Xu and has published in prestigious journals such as Nature Communications, Cancer Research and Scientific Reports.

In The Last Decade

Fujiang Xu

13 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fujiang Xu China 7 180 96 92 49 31 13 281
Yiyi Ji China 7 166 0.9× 99 1.0× 105 1.1× 85 1.7× 51 1.6× 13 309
Mingwen Huang China 10 142 0.8× 54 0.6× 74 0.8× 87 1.8× 24 0.8× 22 279
Daisaku Ashikari Japan 9 218 1.2× 84 0.9× 83 0.9× 72 1.5× 89 2.9× 13 345
Tengyue Zeng China 10 194 1.1× 121 1.3× 144 1.6× 36 0.7× 15 0.5× 19 289
Valen Zhuoyou Yu Hong Kong 10 152 0.8× 64 0.7× 64 0.7× 121 2.5× 54 1.7× 22 276
Lejie Cao China 10 190 1.1× 154 1.6× 51 0.6× 161 3.3× 16 0.5× 17 372
Annie Wai Yeeng Chai Malaysia 7 205 1.1× 50 0.5× 103 1.1× 92 1.9× 31 1.0× 14 314
Dimitris Delakas Greece 9 269 1.5× 90 0.9× 197 2.1× 48 1.0× 17 0.5× 9 391
Loretta De Chiara Spain 13 176 1.0× 65 0.7× 120 1.3× 172 3.5× 20 0.6× 27 359

Countries citing papers authored by Fujiang Xu

Since Specialization
Citations

This map shows the geographic impact of Fujiang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fujiang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fujiang Xu more than expected).

Fields of papers citing papers by Fujiang Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fujiang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fujiang Xu. The network helps show where Fujiang Xu may publish in the future.

Co-authorship network of co-authors of Fujiang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Fujiang Xu. A scholar is included among the top collaborators of Fujiang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fujiang Xu. Fujiang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Xu, Fujiang, Lidan Zhang, Jiang Liu, et al.. (2025). The EZH2 selective inhibitor ZLD1039 attenuates UUO-induced renal fibrosis by suppressing YAP activation. Molecular Biomedicine. 6(1). 36–36. 1 indexed citations
2.
3.
Chang, Kun, Yingji Chen, Wei Zhang, et al.. (2023). DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma. Cancer Research. 83(23). 3940–3955. 66 indexed citations
4.
Xu, Ning, Guoguo Shang, Dingwei Ye, et al.. (2022). Integrated proteogenomic characterization of urothelial carcinoma of the bladder. Journal of Hematology & Oncology. 15(1). 76–76. 38 indexed citations
5.
Xu, Fujiang, Wenhao Xu, Hailiang Zhang, et al.. (2022). Increased DNA Polymerase Epsilon Catalytic Subunit Expression Predicts Tumor Progression and Modulates Tumor Microenvironment of Hepatocellular Carcinoma. Journal of Cancer. 13(9). 2740–2750. 3 indexed citations
6.
7.
Tian, Xi, Wenhao Xu, Fujiang Xu, et al.. (2022). Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. Annals of Medicine. 54(1). 211–226. 13 indexed citations
8.
Wu, Xinqiang, Xi Tian, Fujiang Xu, et al.. (2022). Increased expression of tribbles homolog 3 predicts poor prognosis and correlates with tumor immunity in clear cell renal cell carcinoma: a bioinformatics study. Bioengineered. 13(5). 14000–14012. 6 indexed citations
9.
Xiao, Wenjun, Fujiang Xu, Xuan Zhang, et al.. (2019). The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 9. 879–879. 7 indexed citations
10.
Li, Yang, Fujiang Xu, Yuanyuan Qu, et al.. (2019). APC/CCDH1 synchronizes ribose-5-phosphate levels and DNA synthesis to cell cycle progression. Nature Communications. 10(1). 2502–2502. 69 indexed citations
11.
Ma, Jian, Kun Chang, Jingtao Peng, et al.. (2018). SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Journal of Experimental & Clinical Cancer Research. 37(1). 145–145. 46 indexed citations
12.
Cao, Dalong, Yuanyuan Qu, Xuan Zhang, et al.. (2018). High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma. Journal of Cancer. 9(18). 3400–3406. 2 indexed citations
13.
Xu, Fujiang, Kun Chang, Jian Ma, et al.. (2017). The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. Scientific Reports. 7(1). 9846–9846. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yiyi Ji Breakdown of academic impact, for papers by Mingwen Huang Breakdown of academic impact, for papers by Daisaku Ashikari Breakdown of academic impact, for papers by Tengyue Zeng Breakdown of academic impact, for papers by Valen Zhuoyou Yu Breakdown of academic impact, for papers by Lejie Cao Breakdown of academic impact, for papers by Annie Wai Yeeng Chai Breakdown of academic impact, for papers by Dimitris Delakas Breakdown of academic impact, for papers by Loretta De Chiara
Rankless by CCL
2026